Latest Headlines

  1. Avance Clinical Honored With Frost & Sullivan's 2025 Global Customer Value Leadership Award 5/20/2025

    Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Leadership Award in the biotech contract research organization (CRO) sector, highlighting the company’s outstanding performance in delivering exceptional client value through innovation, service excellence, and technology-enabled trial optimization.

  2. VintaBio Presents Data Demonstrating High-Efficiency AAV Vector Production Using Proprietary VintaProcess™ At 2025 ASGCT Annual Meeting 5/15/2025

    VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary VintaProcess™ at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.  

  3. Novotech Welcomes New Investment From GIC, Temasek, And Existing Investor TPG To Accelerate Global Growth 5/14/2025

    Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announced today that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its global growth. Existing investor TPG will also reinvest through its TPG Asia fund.

  4. Novotech Report Reveals Global Surge In Infectious Disease Trials As Industry Nears 2,000 Studies Since 2020 5/14/2025

    Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released a new report analyzing the evolving infectious disease clinical trial landscape. This report provides critical strategic insights for pharmaceutical and biotech companies navigating the complexities of global infectious disease research and development in 2025. 

  5. Novotech Identifies Strategic Opportunities In Idiopathic Pulmonary Fibrosis Trials With Release Of Global Market Insights 5/14/2025

    Sydney, April 2025 – Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance drug development, has released an in-depth report on the global clinical trial landscape for Idiopathic Pulmonary Fibrosis (IPF). The report offers strategic insights and comprehensive analysis critical for biotech and pharmaceutical companies navigating the complexities of IPF clinical research and drug development. 

  6. 3PBIOVIAN Awarded At The CDMO Leadership Awards 2025 In The Cell & Gene Therapy International Category 5/14/2025
  7. 3PBIOVIAN Unveils Two Groundbreaking Technology Platforms For AAV And pDNA Manufacturing 5/14/2025

    3PBIOVIAN, a trusted CDMO partner in biopharmaceutical manufacturing proudly announced today the launch of AAVion® Platform, a fully integrated adeno-associated virus (AAV) manufacturing solution, designed to accelerate gene therapy development.

  8. Andelyn Biosciences Applies The AAV Curator® Platform To Deliver Novel Gene Therapy For An Ultra-Rare NEDAMSS Disease Patient 14-Months After Diagnosis 5/12/2025

    Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has successfully manufactured a novel viral vector gene therapy with its AAV Curator® Platform to treat a baby with the ultra-rare disease Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS).

  9. VintaBio Unveils New Data Showcasing Scalable AAV Perfusion Manufacturing Platform With High Full Capsid Yield At 2025 ASGCT Annual Meeting 5/8/2025

    VintaBio, a biotech manufacturing technology company specializing in high-yield, high-purity viral vector production for reliable gene therapy access, will present transformative data on its proprietary VintaProcess™, an advanced intensified adherent viral vector manufacturing platform.

  10. Minaris Advanced Therapies Launches As The Leading Global Partner Dedicated To Cell Therapy Development, Manufacturing, And Testing 5/7/2025

    Through strategic acquisitions made by New York–based investment firm Altaris, Minaris Regenerative Medicine and the U.S. and U.K. operations of WuXi Advanced Therapies have been combined to form Minaris Advanced Therapies, a global cell therapy CDMO and testing partner.